News
CSL, Alentis Partner to Develop Lixudebart for Kidney and Liver Diseases
Under the agreement, CSL will make an upfront payment of USD 355 million to Alentis, while Alentis is eligible to receive up to an additional USD 1.2 billion in commercial milestone payments.
imphoenix82
- October 5, 2026
- 0 Comments
- 222 Views
-
